A compelling body of evidence revealed EGCG can downregulate the expression levels of VEGF by inhibiting multiple tumor-related signaling molecules, such as PI3K, Akt, mammalian target of rapamycin (mTOR), hypoxia-inducible factor-1alpha (HIF-1α), NF-κB, and STAT3, thus inhibiting endothelial angiogenesis and tumor progression (16, 86, 141–143). The gene discussed is AKT1; the disease is neoplasm.